These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 6529777)
1. Increased immunogenicity of murine lymphoma cells following exposure to gamma rays in vivo. Guadagni F; Roselli M; Fuggetta MP; Perno CF; Goldin A; Giuliani A Chemioterapia; 1984 Dec; 3(6):358-64. PubMed ID: 6529777 [TBL] [Abstract][Full Text] [Related]
2. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide. Contessa AR; Bonmassar A; Giampietri A; Circolo A; Goldin A; Fioretti MC Cancer Res; 1981 Jun; 41(6):2476-82. PubMed ID: 7016315 [TBL] [Abstract][Full Text] [Related]
3. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy. Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines. Nicolin A; Canti G; Marelli O; Veronese F; Goldin A Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535 [TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline. Testorelli C; Archetti YL; Aresca P; Del Vecchio L Cancer Res; 1985 Nov; 45(11 Pt 1):5299-303. PubMed ID: 4053006 [TBL] [Abstract][Full Text] [Related]
6. Changes of the immunogenic properties of a radiation-induced mouse lymphoma following treatment with antitumor drugs. Bonmassar E; Testorelli C; Franco P; Goldin A; Cudkowicz G Cancer Res; 1975 Aug; 35(8):1957-62. PubMed ID: 1149019 [TBL] [Abstract][Full Text] [Related]
7. In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas. Testorelli C; Franco P; Goldin A; Nicolin A Cancer Res; 1978 Mar; 38(3):830-4. PubMed ID: 75062 [TBL] [Abstract][Full Text] [Related]
8. Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay. Fuji H; Mihich E Cancer Res; 1975 Apr; 35(4):946-52. PubMed ID: 1090366 [TBL] [Abstract][Full Text] [Related]
9. Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity. Fioretti MC; Bianchi R; Romani L; Bonmassar E J Natl Cancer Inst; 1983 Dec; 71(6):1247-51. PubMed ID: 6581361 [TBL] [Abstract][Full Text] [Related]
10. Intracerebral adoptive immunotherapy of a murine lymphoma antigenically altered by drug treatment in vivo. Romani L; Fioretti MC; Bianchi R; Nardelli B; Bonmassar E J Natl Cancer Inst; 1982 May; 68(5):817-22. PubMed ID: 7040772 [TBL] [Abstract][Full Text] [Related]
11. Immunosensitivity and histocompatibility antigens in drug-altered leukemic cells. Nicolin A; Franco P; Testorelli C; Goldin A Cancer Res; 1976 Jan; 36(1):222-7. PubMed ID: 1248001 [TBL] [Abstract][Full Text] [Related]
12. Drug-mediated immunogenic changes of virus-induced leukemia in vivo. Houchens DP; Bonmassar E; Gaston MR; Kende M; Goldin A Cancer Res; 1976 Apr; 36(4):1347-52. PubMed ID: 1260759 [TBL] [Abstract][Full Text] [Related]
13. Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas. Hill HZ; Hill GJ Cancer Res; 1982 Mar; 42(3):838-42. PubMed ID: 7059982 [TBL] [Abstract][Full Text] [Related]
14. DNA methylating activity in murine lymphoma cells treated with xenogenizing chemicals. Puccetti P; Allegrucci M; Borri Voltattorni C; Romani L; Dominici P; Fioretti MC Cancer Detect Prev Suppl; 1987; 1():311-6. PubMed ID: 2446756 [TBL] [Abstract][Full Text] [Related]
15. Differential tumor immunogenicity of L1210 and its sublines. I. Effect of an increased antigen density on tumor cell surfaces on primary B cell responses in vitro. Fuji H; Mihich E; Pressman D J Immunol; 1977 Sep; 119(3):983-6. PubMed ID: 330761 [TBL] [Abstract][Full Text] [Related]
16. Vaccination of leukemic mice with viable drug-altered leukemic cells. Boerio D; Cavalli M; Marelli O; Veronese F; Nicolin A Ric Clin Lab; 1978; 8(3):127-33. PubMed ID: 746293 [TBL] [Abstract][Full Text] [Related]
17. Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene derivatives. Nardelli B; Contessa AR; Romani L; Sava G; Nisi C; Fioretti MC Cancer Immunol Immunother; 1984; 16(3):157-61. PubMed ID: 6561067 [TBL] [Abstract][Full Text] [Related]
18. Immunologic cross-reactivity of antigen(s) induced by drug treatment in two leukemic sublines. Nicolin A; Bini A; Di Padova F; Goldin A J Immunol; 1976 May; 116(5):1347-9. PubMed ID: 58028 [TBL] [Abstract][Full Text] [Related]
19. Two antiemetic regimens do not impair chemical xenogenization induced in vivo by 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide. Ballerini P; Franchi A; Fuschiotti P; Piccioni D; Bonmassar E Cancer Chemother Pharmacol; 1989; 24(6):359-62. PubMed ID: 2791188 [TBL] [Abstract][Full Text] [Related]
20. Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide. Bonmassar E; Bonmassar A; Vadlamudi S; Goldin A Cancer Res; 1972 Jul; 32(7):1446-50. PubMed ID: 4402275 [No Abstract] [Full Text] [Related] [Next] [New Search]